News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
CeNes Pharmaceuticals (U.S.) Starts Recruitment for Phase II trial of CNS 5161 for Cancer Pain
September 12, 2007
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON (Thomson Financial) - CeNeS Pharmaceuticals PLC said it has started recruitment for a Phase II study of the potential new pain drug CNS 5161, which is being developed under a co-development deal with the ERGOMED Group.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
Europe
MORE ON THIS TOPIC
Neuropsychiatric disorders
Draig Takes Flight With $140M Series A To Advance Neuropsych Drugs
June 18, 2025
·
2 min read
·
Tristan Manalac
Approvals
CSL Wins First Approval for Preventive Hereditary Angioedema Drug
June 18, 2025
·
2 min read
·
Tristan Manalac
Parkinson’s disease
Ventyx’s Parkinson’s Pill Shows ‘Promising’ Results in Mid-Stage Study, Paving Path to Other Neuro Diseases
June 17, 2025
·
2 min read
·
Tristan Manalac
Cancer
Roche, AbbVie’s Venclexta Stumbles Again, This Time in Myelodysplastic Syndromes
June 17, 2025
·
1 min read
·
Tristan Manalac
